The impact of new emerging drugs in the treatment of multiple myeloma: Is there still a role for PBSC transplantation?

Current Stem Cell Research and Therapy

Volumn 2, Issue 1, 2007, Pages 1-11

  Corso, Alessandro ^a   Varettoni, Marzia ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Bortezomib; Chemotherapy; Lenalidomide; Thalidomide; Transplantation

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; BORTEZOMIB; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; LENALIDOMIDE; LIPOSOME; MELPHALAN; PAMIDRONIC ACID; PLACEBO; PREDNISONE; PROTEASOME INHIBITOR; STEROID; THALIDOMIDE; VINCRISTINE; WARFARIN;

ANTINEOPLASTIC ACTIVITY; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLEEDING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER THERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG FORMULATION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; GROUPS BY AGE; HEALTH PROGRAM; HEMATOPOIESIS; HUMAN; INTERMETHOD COMPARISON; LOW DRUG DOSE; LUNG EMBOLISM; MEGAKARYOCYTE; META ANALYSIS; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PERIPHERAL BLOOD STEM CELL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SEDATION; SENSORY NEUROPATHY; SEPSIS; SIDE EFFECT; SOMNOLENCE; STEM CELL MOBILIZATION; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; WHOLE BODY RADIATION;

EID: 34248202283     PISSN: 1574888X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488807779316955     Document Type: Review

References (96)

1. Barlogie B, Hall R, Sander A, et al. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 1986; 67: 1298-1301.
2. Barlogie B, Alexanian R, Dicke KA, et al. High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 1987; 70: 869-872.
3. Dimopoulos MA, Alexanian R, Przepiorka D, et al. Thiotepa, busulphan and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. Blood 1993; 82: 2324-2328.
4. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996; 335: 91-97.
5. Attal M. Updated Results IFM90. Abstracts of International Myeloma Workshop, Banff, Canada.
6. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003; 348: 1875-1883.
7. Fermand JP, Katsahian S, Divine M, et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the group Myeloma-Autogreffe. J Clin Oncol 2005; 23(36): 1-7.
8. Bladè J, Rosiñol L, Sureda A, et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005; 106, 12: 3755-3759.
9. Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006; 24, 6: 929-936.
10. Smith A, Wisloff F, Samson D. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol, 132: 410-451.
11. 2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002; 99: 731-735.
12. Lahuerta JJ, Grandé C, Bladé J, et al. Myeloablative treatments for multiple myeloma: update of a comparative study of different regimens used in patients from the Spanish registry for transplantation in multiple myeloma. Leukemia and Lymphoma 2002; 43: 67-74.
13. Ria R, Falzetti F, Ballanti S, et al. Melphalan versus melphalan plus busulphan in conditioning to autologous stem cell transplantation for low-risk multiple myeloma. Hematology Journal 2004; 5: 118-122.
14. Siegel DS, Desikan KR, Mehta J, et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 1999; 93: 51-54.
15. Sirohi B, Powles R, Treleaven J, et al. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplant 2000; 25: 533-539.
16. Terpos E, Apperley JF, Samson D, et al. Autologous stem cell trasplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma, but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients. Bone Marrow Transplant 2003; 31: 163-170.
17. Reece DE, Bredeson C, Perez WS, et al. Autologous stem cell transplantation in multiple myeloma patients <60 vs ≥60 years of age. Bone Marrow Transplant 2003; 32: 1135-1143.
18. Badros A, Barlogie B, Morris C, et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 2001; 114: 600-607.
19. Palumbo A, Triolo S, Argentino C, et al. Dose intensive melphalan with stem cell support (MEL 100) is superior to standard treatment in elderly myeloma patients. Blood 1999; 94: 1248-1253.
20. Palumbo A, Bringhen S, Petrucci MT, et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50-70: results of a randomized controlled trial. Blood 2004; 104: 3052-3057.
21. Sirohi B, Powles R, Kulkami S, et al. Maximal response to infusional chemotherapy prior to autotransplantation influences the outcome of patients with newly diagnosed multiple myeloma. Bone Marrow Transplant 2001; 27: S246.
22. Björkstrand B, Goldstone AH, Ljumgman P, et al. Prognostic factors in autologous stem cell transplantation for multiple myeloma: an EBMT Registry Study. European Group for Bone Marrow Transplantation. Leuk Lymphonia. 1994; 15(3-4): 265-272.
23. Alegre A, Diaz-Mediavilla J, San-Miguel J, et al. Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry. Spanish Registry for Transplant in MM (Grupo Espanol de Trasplante Hematopoyefico-GETH) and PETHEMA. Bone Marrow Transplant. 1998; 21(2):133-40.
24. Singhal S, Powles R, Sirohi B, et al. Response to induction therapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma. Blood 2001; 98: 816a.
25. Kumar S, Lacy MQ, Dispensieri A, et al. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplant 2004; 34: 161-167.
26. Rajkumar SV, Fonseca R, Lacy MQ, et al. Autologous stem cell transplantation for relapsed and primary refractory myeloma. Bone Marrow Transplant 1999; 23: 1267-1272.
27. Alexanian R, Weber D, Delasalle K, et al. Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma. Bone Marrow Transplant 2004; 34: 229-234.
28. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6.633 patients from 27 randomized trials. J Clin Oncol 1998; 16: 3832-3842.
29. Abrahamson GM, Bird JM, Newland AC, et al. A randomized study of VAD therapy with either concurrent or maintenance interferon in patients with newly diagnosed multiple myeloma. Br J Haematol 1996; 94: 659-664.
30. Alexanian R, Barlogie B, Tucker S: VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 1990; 33: 86-89.
31. Samson D, Gaminara E, Newland A, et al: infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet 1989; 2:882-885.
32. Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55-65.
33. Attal M, Harousseau JL, Facon T et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 25: 2495-2502.
34. Cavo M, Zamagni E, Cellini C, et al. Single versus tandem autologous transplants in multiple myeloma: Italian experience. Haematologica 2005; 90(suppl 1): 38.
35. Sonneveld P, van der Holt B, Segeren CM, et al. Intensive versus double intensive therapy in untreated multiple myeloma. Updated results of the prospective phase III study Hovon 24-MM. Haematologica. 2005; 90(suppl 1): 37-38.
36. Fermand JP, Marolleau JP, Alberti C, et al. for the Group Myelome-Autogreffe. Single versus tandem high dose therapy supported with autologous stem cell transplantation using unselected or CD34 enriched ABSC: preliminary results of a two by two designed randomized trial in 23 young patients with multiple myeloma. Blood 2001; 98: 815a (abstract).
37. Björkstrand B, Svensson H, Goldschmidt H, et al. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Bone and Marrow Transplantation (EBMT). Bone Marrow Transplant 2001; 27: 511-515.
38. Cunningham D, Powles R, Malpas J, et al. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results. Br J Haematol 1998; 102: 495-502.
39. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-1571.
40. Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98: 492-494.
41. Tosi P, Zamagni E, Cellini C, et al. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica 2002; 87: 408-414.
42. Yakoub-Agha I, Attal M, Dumontet C, et al. Thalidomide in patients with advanced multiple myeloma: a study of 83 patients - report of the intergroupe francophone du myelome (IFM). Hematol J 2002; 3(4): 185-192.
43. Leleu X, Magro L, Fawaz A, et al. Efficacy of low dose thalidomide in advanced multiple myeloma. Blood 2002; 100: 1519-1520.
44. Pini M, Baraldi A, Pietrasanta D, et al. Low-dose thalidomide in the treatment of refractory myeloma. Haematologica 2000; 85: 1111-1112.
45. Hideshima T, Chauhan D, Shima Y et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000; 96: 2943-2950.
46. Weber DM, Gavino M, Delasalle K et al. Thalidomide alone or with dexamethasone for multiple myeloma. Blood 1999; 94: 604 (abstract).
47. Palumbo A, Gaccone L, Bertola A, et al. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica 2001; 86: 399-403.
48. Palumbo A, Bertola A, Falco P, et al. Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol J 2004; 5(4): 318-324.
49. Lee CK, Barlogie B, Munshi N, et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol 2003; 21: 2732-2739.
50. Dimopoulos MA, Hamilos G, Zomas A, et al. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematol J 2004; 5: 112-7.
51. Oakervee H, Brownell A, Cervi P, et al. A study of the safety and efficacy of thalidomide combined with vincristine, adriamycin and dexamethasone (T-VAD) in the treatment of younger patients with multiple myeloma: a UK Myeloma Forum Pilot Study. Br J Haematol 2002; 117 (Suppl. 1): 65.
52. Moehler TM, Neben K, Hawighorst H, et al. Thalidomide plus CED chemotherapy as salvage therapy in poor prognosis multiple myeloma. Blood 2000; 96: 290 (abstract).
53. Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001; 98: 1614-1615.
54. Zangari M, Barlogie B, Hollmig K et al. Marked activity of Velcade plus Thalidomide (V+T) in advanced and refractory Multiple Myeloma. Blood 2004; 104: abstract 1480.
55. Terpos E, Anagoostopoulos A, Kastritis E et al. The combination of Bortezomib, melphalan, dexamethasone and intermittent thalidomide (VMDT) is an effective treatment for relapsed/refractory myeloma: results of a phase II clinical trial. Blood 2005; 106: abstr 363
56. Zangari M, Siegel E, Barlogie B, et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implication for therapy. Blood 2002; 100: 1168-1171.
57. Isoardo G, Bergui M, Durelli L, et al. Thalidomide neuropathy: clinical, electrophysiological and neuroradiological features. Acta Neurol Scand 2004; 109: 188-193.
58. Cavaletti G, Beronio A, Reni L, et al. Thalidomide sensory neurotoxicity. A clinical and neurophysiologic study. Neurology 2004; 62: 2291-2293.
59. Tosi P, Zamagni E, Cellini C, et al. Neurological toxicity of longterm (<1 yr) thalidomide therapy in patients with multiple myeloma. Eur J Haematol 2005;74: 212-216.
60. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients receiving thalidomide: implications for therapy. Blood 2002; 100: 3063-3067.
61. Zangari M, Tricot G, Seldis J, et al. Results of phase I study of CC-5013 for the treatment of multiple myeloma (MM) in patients who relapse after high-dose chemotherapy (HDCT). Blood 2001; 98; 775a (abstract).
62. Weber D: Two phase III randomized, double-blind, placebo-controlled trials of lenalidomide-dexamethasone vs dexamethasone for refractory or relapsed multiple myeloma. Presented at a special session titled: ImiDs-Results of Phase III Studies in Relapsed/Refractory Myeloma. www.ASCO.org (Virtual Meeting), 2005, accessed June 22, 2005.
63. Dimopoulos MA, Spencer A., Attal M, et al Study of Lenalidomide Plus Dexamethasone Versus Dexamethasone Alone in Relapsed or Refractory Multiple Myeloma (MM): Results of a Phase 3 Study (MM-010). Blood (ASH Annual Meeting Abstracts) 2005 106: abstract 6.
64. Hideshima T, Richardson P, Chaunan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61: 3071-3076.
65. Richardson PG, Barlogie B; Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617.
66. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed refractory myeloma. Br J Haematol 2004; 127: 165-172.
67. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498.
68. Richardson PG, Sonneveld P, Schuster M, et al. Bortezomib continues demonstrate superior efficacy compared with high-dose dexamethasone in relapsed multiple myeloma. Updated results of the APEX trial. Blood (ASH Annual Meeting Abstracts), Nov 2005; 106: 2547.
69. Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003; 101: 2377-2380.
70. Orlowski RZ, Voorhees PM, Garcia RA, et al. Phase I trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005; 105: 3058-3065.
71. Berenson JR, Yang HH, Sadler K, et al. Phase 17II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 2006; 24: 937-944.
72. Zangari M, Barlogie B, Burns MJ, et al. Velcade(V)-Thalidomide(T)-Dexamethasone(D) for advanced and refractory multiple myeloma (MM): long-term follow-up of phase I/II trial UARK 2001-37: superior outcome in patients with normal cytogenetics and no prior Thalidomide. Blood (ASH Annual Meeting Abstracts), 2005; 106: 2552.
73. Richardson P, Schlossman R, Munsi N, et al. A phase I trial of Lenalidomide (REVLIMID) with Bortezomib (VELCADE) in relapsed, and refractory multiple myeloma. Blood (ASH Annual Meeting Abstracts), 2005; 106: 365.
74. Richardson PG, Briemberg H, Jagannath S et al. Characterization and reversibility of peripheral neuropathy in patients with advanced multiple myeloma treated with bortezomib (VELCADE). The SUMMIT and CREST Study Group. Hematol J 2004; 5 (suppl 2): S129.
75. Lonial S, Waller EK, Richardson P et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 2005; 106 (12): 3777-3784.
76. Fitzgerald M, Fraser C, Webb I et al. Normal hematopoietic stem cell function in mice following treatment with bortezomib. Biol Blood Marrow Transplant, 2003; 9: 193.
77. Liu F, Morris S, Epps J, et al. Demonstration of an activation regulated NF-kappa B/I-kappaB-alpha complex in human platelets. Thromb Res 2002; 106: 199-203.
78. Weber D, Rankin K, Gavino M, et al. thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21: 16-19.
79. Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20: 4319-4323.
80. Cavo N, Zamagni E, Tosi P, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005; 106: 35-39.
81. Barlogie B, Tricot G, Shaughnessy J, et al. Results of total therapy 2 (TT2), a phase III randomized trial, to determine the role of thalidomide (THAL) in the upfront management of multiple myeloma (MM). J Clin Oncol 2005; 23(suppl 16): 560s (abstract LBA6502).
82. Richardson P, Cbanan-Khan A, Schlossman R, et al. A multicenter phase II trial of Bortezomib in patients with previously untreated multiple myeloma: efficacy with manageable toxicity in patients with unexpectedly high rates of baseline peripheral neuropathy. Blood (ASH Annual Meeting Abstracts), 2005; 106: 2548.
83. Jagannath S, Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for patients with previously untreated multiple myeloma. Haematologica 2005; 90 (suppl 1): 148-149.
84. Harousseau JL, Attal M, Coiteux V, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: preliminary results of an IFM phase II study. J Clin Oncol 2005; 23 (suppl 16): 598s (abstract 6653).
85. Oakervee HE, Popat R, Curry N, et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005; 129: 755-762.
86. Alexanian R, Wang LM, Weber DM, et al. VTD (Bortezomib, thalidomide, dexamethasone) as primary therapy for newly diagnosed multiple myeloma. Blood 2004; 104: 64a.
87. Barlogie B, Hollmig K, Zangari M, et al. Total therapy 3 (TT3) for newly diagnosed myeloma, incorporating Bortezomib into remission induction with DT-PACE: early results regarding efficacy, PBSC mobilization and toxicities. Blood 2004; 104: 156a.
88. Uy GL, Fisher NM, Devine SM, et al. Bortezomib does not impair cytokine induced mobilization of stem cells prior to autologous transplantation in multiple myeloma. Blood (ASH Annual Meeting Abstracts), 2005; 106: 2926.
89. Rajkumar SV, Hayman S, Lacy MQ, et al. Combination therapy with CC-5013 (lenalidomide, Revlimid) plus dexamethasone (Rev/Dex) for newly diagnosed myeloma (MM). Blood 2004; 104: 658a (abstract 2397).
90. Protocol ECOG-E4A03. Lenalidomide and dexamethasone with or without thalidomide in treating patients with multiple myeloma.
91. Hollmig K, Stover J, Talamo G, et al. Addition of Bortezomib to high-dose melphalan as an effective conditioning regimen with autologous stem cell support in multiple myeloma. Blood 2004; 104: 266a (abstract 929).
92. Stewart AK, Chen CI, Howson-Jan K, et al. Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant. Clin Cancer Res 2004; 10: 8170-8176.
93. Sahebi F, Spielberger R, Kogut NM, et al. Maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma. Bone Marrow Transplant 2006; 27 March: 1-5.
94. Feyler S, Rawstron A, Jackson G et al. Thalidomide Maintenance following high dose therapy in multiple myeloma: a UK Myeloma Forum phase 2 study. Blood 2005; 106: abstr 641
95. Attal M, Harousseau JL, Leyvraz S, et al. Maintenance treatment with thalidomide after autologous transplantation for Myeloma: final analysis of a prospective randomized study of the Intergroupe Fracophone du Myelome (IFM 99 02). Blood 2005; 106: 1148a (abstract).
96. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354: 1021-1030.